ValiRx Share News (VAL)

ValiRx Completes YA Global Master Equity Swap Deal Early

Valirx's lung cancer treatment receives positive results

Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments. The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrate

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

ValiRx Says Preclinical Trials For VAL401 In Lung Cancer Positive

ValiRx Narrows Half-Year Loss On Lower Costs, Progresses Pipeline

UK MIDDAY BRIEFING: HSBC Results Below Expectations

UK WINNERS & LOSERS: HSBC And Intertek Rise Despite Lower Profit

ValiRx Gets Authorisation For VAL201 Trials, Shares Jump

UK MORNING BRIEFING: UK Shares Flat Ahead Of HSBC Results

DIRECTOR DEALINGS: ValiRx Directors Buy 5.3 Million Shares

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6